PALATIN TECHNOLOGIES
We are a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our primary product in clinical development is bremelanotide for the treatment of female sexual dysfunction (FSD). In addition, we have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases and inflammatory diseases. The following drug development programs are actively under development:
PALATIN TECHNOLOGIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
1986-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Website Url:
http://www.palatin.com
Total Employee:
11+
Status:
Active
Contact:
609-495-2200
Email Addresses:
[email protected]
Total Funding:
104.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Current Employees Featured
Founder
Stock Details
Investors List
QVT Financial
QVT Financial investment in Post-IPO Equity - Palatin Technologies
Horizon Technology Finance
Horizon Technology Finance investment in Post-IPO Debt - Palatin Technologies
Alexandra Investment Management
Alexandra Investment Management investment in Post-IPO Equity - Palatin Technologies
Lurie Investment Fund
Lurie Investment Fund investment in Post-IPO Equity - Palatin Technologies
Albert Fried & Company
Albert Fried & Company investment in Post-IPO Equity - Palatin Technologies
Lombard Odier
Lombard Odier investment in Post-IPO Equity - Palatin Technologies
Perry Capital
Perry Capital investment in Post-IPO Equity - Palatin Technologies
NAI Elliott
NAI Elliott investment in Post-IPO Equity - Palatin Technologies
Deutsche Bank
Deutsche Bank investment in Post-IPO Equity - Palatin Technologies
Bank Clariden Leu
Bank Clariden Leu investment in Post-IPO Equity - Palatin Technologies
Official Site Inspections
http://www.palatin.com Semrush global rank: 4.17 M Semrush visits lastest month: 2.85 K
- Host name: palatin.tempurl.host
- IP address: 108.61.155.191
- Location: Paterson United States
- Latitude: 40.9138
- Longitude: -74.1896
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07502
More informations about "Palatin Technologies"
The Palatin Group - Global Intelligence, Security and Advisory
The Palatin Group is particularly experienced and well-versed in addressing the inherent risks of energy development, extraction, and production in unstable or hostile environments, …See details»
Palatin Technologies | About Us
CARL SPANA, PhD, co-founder of Palatin, has been our Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a …See details»
Palatin Technologies - Crunchbase Company Profile & Funding
Palatin Technologies reported a net loss of $2.4 million for the quarter ended December 31, 2024, compared to a net loss of $7.8 million for the same period in 2023. The company announced a …See details»
Leadership - The Palatin Group
The Palatin Group LTD; 3100 Clarendon Blvd. Suite 200 Arlington, VA 22201 +1 202 894 7121; CENTRAL EUROPE. Palatin Group SK s.r.o. 29. Augusta 36 811 09 Bratislava, Slovakia +421 …See details»
Palatin Technologies - LinkedIn
Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor …See details»
The Palatin Group - Crunchbase Company Profile & Funding
Palatin Grp. provides global intelligence, security, and advisory services. The company offers specialized expertise to help clients mitigate risk, protect assets, and realize opportunities. …See details»
PALATIN TECHNOLOGIES, INC.
PALATIN TECHNOLOGIES, INC. Corporate Presentation I June 2021 Carl Spana, Ph.D. President & CEO Stephen T. Wills, CPA/MST CFO / COO. Forward Looking Statements The …See details»
About Us - The Palatin Group
The name Palatin was derived from the word palatine. In ancient Rome, a palatine was a powerful authority, an advisor or protector. Like the palatines in ancient Rome, The Palatin Group is …See details»
The Palatin Group - LinkedIn
The Palatin Group | 1,260 followers on LinkedIn. Global intelligence, security, and advisory services firm | Palatin Group is a global intelligence, security and advisory services firm …See details»
Palatin Technologies, Inc. (PTN) - Yahoo Finance Canada
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead …See details»
Palatin - Overview, News & Similar companies | ZoomInfo.com
Who is Palatin. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various dis eases in the United …See details»
Home - Palatin
Recruitment done right! At Palatin, we are committed to connecting ambitious IT talents with the organizations that need them the most: providing a tailored, efficient, and personalized …See details»
Palatin stock gains on FDA Orphan Drug status (PTN:NYSE)
2 days ago Palatin Technologies (PTN) stock rises as FDA grants orphan drug status to PL7737, its experimental drug for leptin receptor deficiency. Read more here.See details»
Palatin Technologies | Corporate Governance
Palatin maintains a Reporting Hotline for reporting suspected violations of our Code of Corporate Conduct and Ethics. Palatin is determined to operate in conformity with applicable laws and …See details»
Palatin Technologies Announces FDA Orphan Designation For
2 days ago Carl Spana, President and CEO of Palatin, said: "Currently, the only FDA-approved treatment for obesity due to leptin receptor deficiency is a daily injection. PL7737's oral form …See details»
Services - The Palatin Group
The Palatin Group’s complete suite of process-driven and goal-focused global intelligence and advisory services include: ... When an organization or individual is aware of potential risks to …See details»
All Eyes on Palatin Technologies as Major Obesity Trial Results Near
Feb 11, 2025 Palatin Technologies has completed its closely watched Phase 2 BMT-801 clinical trial, with results expected before the end of March 2025. The study, which drew unexpectedly …See details»
Palatin Announces $4.7 Million Registered Direct Offering and ...
CRANBURY, N.J., Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class …See details»
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug …
2 days ago "This FDA orphan designation is a key step in developing Palatin's MC4R receptor agonists for rare obesity conditions," said Carl Spana, Ph.D., President and CEO of Palatin. …See details»
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial …
Nov 14, 2024 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the …See details»